Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 4/20 | 0.74 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.74 |
| ▸ | GRIA3 | P42263 | 4/20 | 0.74 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.74 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.74 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.74 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.74 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.74 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.74 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.74 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tqx-173 SCHEMBL2038719 | 0.78 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL13227262 | 0.77 | GRIN2D (0.73) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL405914 | 0.76 | GRIN2D (0.73) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL6608200 | 0.68 | GRIN2D (0.70) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL1292035 | 0.67 | GRIA2 (0.74) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL8559477 | 0.66 | CHEK1 (0.51) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL7354337 | 0.66 | GRIN2D (0.42) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL8612021 | 0.65 | GRIA1 (0.72) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL9038023 | 0.65 | GRIA1 (0.50) | GRIA1GRIA2GRIA3GRIA4GRIN2D | |
| SCHEMBL7484219 | 0.63 | GRIA1 (0.61) | GRIA1GRIA2GRIA3GRIA4GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | GRM5, GRM1, GRM3 | GRIA1 10/4885GRIA2 13/4885GRIA3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.